Impact of Gene Polymorphism of Lipoprotein Lipase on Atorvastatin Treatment Outcome in Ischemic Stroke Patient in Najaf Governorate
European Journal of Molecular & Clinical Medicine,
2020, Volume 7, Issue 2, Pages 225-228
AbstractBackground: Stroke was commonly identified as a neurologically impairment that occur in central nervous system on vascular basis as Acute focal injury. Statin (HMG-CoA reductase Inhibitor), clinical trials in many large scaled shown that in primary and secondary CVD the used of statin was declined rates of (CV). Human Lipoprotein Lipase (LPL) gene coding was place in short arm of chromosome in the p22 region of the same Chromosome and has nine introns and ten axons. Aim: The aim of the study is to find out effect of LPL gene polymorphism of response to atorvastatin treatment in patients with ischemic stroke. Patients and methods: Samples was Picking up from patients’ admission to at Middle Euphrates Center for Neurological Sciences in the main hospital for measurement of the lipid profile, molecular analysis study of genotyping and measurement of human lipoprotein lipase by ELISA technique. Result: There is good response to treatment and the response consider statistically significant, the best group response to treatment was homozygous mutation then Heterozygous mutation and the less group response was Homozygous normal, wild. Conclusion: The effect of drug on serum biomarker not affected by age except HDL (best result in age<60yr), and not affected by gender and weight state, while in consider to smoking and Hypertension TG (best response in non-smoker, hypertensive) and VLDL (best response in smoker, hypertensive) affected and in diabetic state the Cholesterol and TG affected on response (the best result in non-diabetic). Heterozygous mutation most distributed then homozygous normal and the less distributed was homozygous mutation.
- Article View: 161
- PDF Download: 228